✦ LIBER ✦

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

✍ Scribed by Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T.

Book ID: 119320518
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 216 KB
Volume: 71
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2010.12.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 144 KB

OP3 Cost-effectiveness of epidermal grow

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

✍ G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

Cost-effectiveness of epidermal growth f

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Prospective Phase II Study of Gefitinib

Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

✍ Inoue, A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 262 KB